Skip to main content
OpenTrials
Completed

NCT Number: NCT04264767

Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA

Nucleix EpiCheck® tests analyzes the methylation pattern in a panel of DNA methylation biomarkers and determines whether this pattern is consistent with cancer under test or with non-cancer tissue.

This study is being performed as part of the development process of the Pan Cancer EpiCheck test which includes the identification of different methylation profiles in various cancer types and healthy controls.

Completed

Looking for future studies?

Notify Me

Key information

Age range

22 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Sourasky Medical Center, Tel Aviv, Israel

Loading trial locations.

About this study

The aim of this study is to characterize methylation patterns that will distinguish cancer from normal samples and will be able to recognize the origin of the cancer by collecting cfDNA (circulating free DNA) from blood samples collected from patients with a new diagnosis of cancer and from healthy volunteers who do not have diagnosis or history of cancer. Identifying those methylation patterns may assist in the development of blood test that will be able to detect the presence and the origin of wide range of human cancers

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

- Cases:

  • Age ≥ 22 years
  • Subjects who are willing and able to provide written informed consent.
  • Subjects with confirmed diagnosis of cancer (primary or recurrent) at all stages, however did not yet undergo any surgery, chemotherapy, radiation or any other treatment for this cancerous lesion (including, but not limited to systemic therapies). Recent cancer staging should be within 60 days prior to baseline visit.

Exclusion criteria

- Cases:

  • Known prior diagnosis of cancer except of:
  • Fully resected non-melanoma skin cancer
  • History of the original cancer in cases of recurrent disease.
  • Current co-diagnosis of another type of cancer.
  • Currently receiving, or ever received, any of the following therapies to treat their current cancer: surgical management of the cancer beyond that required to establish the cancer diagnosis; local, regional or systemic chemotherapy including chemoembolization; targeted therapy, immunotherapy including cancer vaccines; hormone therapy; or radiation therapy
  • Pregnancy (by self-report)
  • Current febrile illness
  • Acute exacerbation or flare of an inflammatory condition requiring escalation in medical therapy within 14 days prior to blood draw.
  • Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant

Inclusion criteria

- Controls:

  • Age 45 to 80 years
  • Subjects who are willing and able to provide written informed consent

Exclusion criteria

- Controls:

  • Known current or prior diagnosis of cancer except of fully resected non-melanoma skin cancer
  • Currently in work-up due to suspicion of cancer of any kind
  • Oral or IV corticosteroid use in past 14 days prior to blood draw
  • Pregnancy (by self-report)
  • Current febrile illness
  • Acute exacerbation or flare of an inflammatory condition requiring escalation in medical therapy within 14 days prior to blood draw.
  • Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant
  • Life expectancy < 24 months

Treatment and study plan

Blood Collection

Procedure

Peripheral blood collection via routine venipuncture

Primary outcomes

  1. To collect blood and urine samples and clinical data in order to characterize methylation patterns that will discriminate cancer and normal (non-cancer) samples and the origin of cancer

    Time frame: 72 Months

    To collect blood and urine samples and clinical data in order to characterize methylation patterns that will discriminate cancer and normal (non-cancer) samples and the origin of cancer

  2. To develop a molecular blood test that will be able to detect wide range of human cancers based on change in methylation patterns between cancer and normal samples

    Time frame: 72 Months

    To develop a molecular blood test that will be able to detect wide range of human cancers based on change in methylation patterns between cancer and normal samples

Sponsors and collaborators

Lead sponsor

Nucleix Ltd.

Industry

Registry information

Official study title

Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA, An Observational Multicenter Study

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Feb 11, 2020
Registry last updated
Jun 8, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.